Specific inhibition of the TSP-1/CD47 interaction with a peptide antagonist decreases GBM cell invasion.255 CD47 is also expressed highly in ovarian cancer, HCC, cholangiocarcinoma (CCA), etc. High expression of CD47 may contribute to the resistance of CSCs to chemotherapy.256 In HER2-expressing cells, CD47 is upregulated preferentially, and the interaction between CD47 and HER2 is reflected in the significant difference in the expression levels of CD47 in HER2+ versus HER2− breast cancer cells. The gene discussed is ERBB2; the disease is glioblastoma.